Zhongguancun: The application for the marketing authorization of Ivabradine hydrochloride tablets has been accepted.

Announcement from Zhongguancun, subsidiary company Duoduo Pharmaceutical Co., Ltd. recently received the "Acceptance Notice" issued by the National Medical Products Administration, indicating that the application for the marketing authorization of Ivabradine Hydrochloride Tablets has been accepted. Ivabradine Hydrochloride Tablets are indicated for patients with sinus rhythm and a heart rate 75 beats/minute, accompanied by NYHA II-IV chronic heart failure with impaired cardiac contractility, in combination with standard treatment including beta-blockers, or for use in patients who are contraindicated or intolerant to beta-blocker treatment. As of the date of this announcement, the cumulative research and development expenses for Ivabradine Hydrochloride Tablets project have reached 3.6428 million yuan.